The analysis of Aβ-42, total tau protein, and phosphorylated tau (p-tau) from cerebrospinal fluid (CSF) is currently considered the best-established biological marker for the diagnosis of AD as well as differentiation from mild cognitive impairment and other types of dementia. This evidence concerns the gene MAPT and Alzheimer disease.